(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 9.89%
Live Chart Being Loaded With Signals
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States...
Stats | |
---|---|
今日成交量 | 332 451 |
平均成交量 | 669 651 |
市值 | 31.30M |
EPS | $0 ( 2024-03-28 ) |
下一个收益日期 | ( $-0.0600 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.890 |
ATR14 | $0.00200 (0.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Fair John A | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-03-12 | Johnson Sabrina Martucci | Buy | 750 000 | Employee Stock Option (right to buy) |
2024-03-12 | Haring-layton Mardee | Buy | 290 000 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 3 500 | Employee Stock Option (right to buy) |
2024-01-26 | Haring-layton Mardee | Sell | 30 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
78.65 |
Last 91 transactions |
Buy: 10 072 923 | Sell: 492 500 |
音量 相关性
Dare Bioscience Inc 相关性 - 货币/商品
Dare Bioscience Inc 财务报表
Annual | 2023 |
营收: | $2.81M |
毛利润: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2023 |
营收: | $2.81M |
毛利润: | $2.77M (98.63 %) |
EPS: | $-0.350 |
FY | 2022 |
营收: | $10.00M |
毛利润: | $9.95M (99.52 %) |
EPS: | $4.81 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.630 |
Financial Reports:
No articles found.
Dare Bioscience Inc
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。